Treatment of Tardive Dyskinesia Due to Olanzapine
The first-line treatment for tardive dyskinesia (TD) caused by olanzapine is gradual withdrawal of the medication if clinically feasible, followed by switching to an antipsychotic with lower TD risk such as clozapine if continued antipsychotic treatment is necessary. 1, 2
Initial Management Approach
- If clinically possible, gradually withdraw olanzapine as abrupt discontinuation may exacerbate TD symptoms 1, 2
- When continued antipsychotic treatment is necessary, consider switching to an atypical antipsychotic with lower D2 receptor affinity and reduced TD risk 1, 3
- Clozapine has shown effectiveness in treating olanzapine-induced TD and should be considered when clinically appropriate 4, 5
- Regular monitoring using standardized measures like the Abnormal Involuntary Movement Scale (AIMS) is essential to track progression and treatment response 1, 6
Pharmacological Options
- VMAT2 inhibitors like deutetrabenazine have FDA approval specifically for TD treatment and demonstrated statistically significant improvement in AIMS scores in clinical trials 7
- When using deutetrabenazine (AUSTEDO), start at 6 mg per day and titrate upward at weekly intervals in 6 mg increments until satisfactory control of dyskinesia is achieved 7
- Clozapine has shown particular efficacy in treating TD, with case reports documenting successful resolution of olanzapine-induced TD symptoms within weeks of switching 4, 5
- Be aware that clozapine requires extensive monitoring due to risk of agranulocytosis (approximately 1% of patients) and seizures (approximately 3% of patients) 3
Prevention and Monitoring
- Baseline assessment of abnormal movements should be documented before starting any antipsychotic therapy 1, 6
- Regular monitoring for TD should occur at least every 3-6 months using standardized measures like AIMS 1, 6
- Early detection is crucial as TD may persist even after medication discontinuation 1
- The risk of developing TD increases with longer duration of treatment and higher cumulative doses of antipsychotics 2
Special Considerations
- TD can develop after prolonged treatment with olanzapine despite its lower risk profile compared to conventional antipsychotics 4, 8
- Some studies suggest that olanzapine itself may reduce TD symptoms when used to replace conventional antipsychotics, but this effect may be masking rather than treating the underlying condition 9, 10
- The concern over TD should not outweigh potential benefits of antipsychotics for patients who genuinely need these medications, but informed consent regarding TD risk is necessary 1, 6
Clinical Pitfalls to Avoid
- Avoid abrupt discontinuation of olanzapine as this may worsen TD symptoms 2, 5
- Don't assume TD is irreversible - early intervention can lead to symptom improvement or resolution in some cases 4, 9
- Be aware that patients may simultaneously have more than one tardive syndrome (e.g., tardive dyskinesia, tardive dystonia, tardive akathisia) requiring different treatment approaches 5
- Remember that even "atypical" antipsychotics like olanzapine can cause TD, particularly with long-term use 4, 8